Press release
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43 (P =
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P Restoring impaired autophagy as early event, preceding amyloid-beta and tau Oral presentation at the Alzheimer’s Association International Conference (AAIC) 2025 NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today the latest findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer’s disease. The data were presented by Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board at the 2025 Alzheimer's Association International Conference (AAIC), held in Toronto. The ATTENTION-AD (ANAVEX®2-73-AD-EP-004) open-label extension (OLE) Phase IIb/III treatment trial followed the 48-week ANAVEX®2-73-AD-004 double-blind (DB) clinical trial, with a combined duration of up to 192 weeks. The trial was designed to evaluate the safety and tolerability of blarcamesine as well as its long-term effects on cognition (ADAS-Cog13) and function (ADCS-ADL) in participants with early Alzheimer’s disease.1 Blarcamesine-treated patients continue to accrue benefit through up to 4 years, as measured by the prespecified clinical endpoints ADAS-Cog13 and ADCS-ADL, respectively. In the intent-to-treat (ITT) population, delayed-start analysis of treatment with oral blarcamesine was significant for both cognition and function, reflecting the importance of early treatment initiation. For ADAS-Cog13 a significant difference between the early-start and late-start treatment groups at Week 192 (LS mean difference −3.83, P = 0.0165) was observed.2 Similarly, for ADCS-ADL at Week 192 statistical significance (LS mean difference +4.30, P = 0.0206) was reached, both favoring the early-start group. Additionally, the GWAS-identified3 population ABCLEAR24, with a global frequency of ~71.7%5, showed further improvement in both cognition, ADAS-Cog13 (LS...